Format

Send to

Choose Destination
J Hepatol. 2008 May;48(5):747-55. doi: 10.1016/j.jhep.2008.01.027. Epub 2008 Feb 25.

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

Author information

1
INSERM U871, Laboratoire des virus hépatiques et pathologies associées, 151 cours Albert Thomas, Lyon cedex 03, France.

Abstract

BACKGROUND/AIMS:

Recent clinical observations reported the occurrence of amino acid substitutions at position 181 of the HBV polymerase, associated with a viral breakthrough under lamivudine or adefovir therapy. In this study, we characterized the main variants harboring the rtA181T/V mutation isolated from 10 consecutive patients who developed lamivudine and/or adefovir resistance.

METHODS:

We performed a clonal analysis of the HBV polymerase gene amplified by PCR from serum samples during viral breakthrough. The main mutants were then tested after transfection of Huh7 cells for their resistance profile to nucleoside analogs.

RESULTS:

Clonal analysis revealed the co-localization on the same HBV genome of rtA181T/V with rtN236T, but not with rtM204V/I mutations following lamivudine, adefovir or lamivudine+adefovir breakthrough. In cell culture, the rtA181T/V mutation induced a decreased susceptibility to lamivudine (<10-fold), adefovir (2- to 8-fold) and tenofovir (2- to 3-fold). Interestingly, the association of rtA181T with rtN236T on one clinical isolate genome increased the resistance to these three drugs. All the tested mutants remained sensitive to entecavir.

CONCLUSIONS:

Our observations suggest that a single amino acid change at position rt181 may induce cross-resistance to lamivudine and adefovir. These data emphasize the clinical relevance of genotypic and phenotypic analysis in the management of antiviral drug resistance.

PMID:
18331765
DOI:
10.1016/j.jhep.2008.01.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center